On Nov 2, 2021 Antiva Biosciences closed a Series D round and raised $31,000,000 from Adjuvant Capital, Alexandria Venture Investments, Avestria Ventures, Brace Pharma, Canaan Partners, Dong-A ST, Gaingels, GV, HBM Healthcare Investments AG, Lumira Ventures, Mana Ventures, OUP (Osage University Partners), Sirona Capital, Sofinnova Investments, featuring lead investors Adjuvant Capital.

About the company: Antiva Biosciences is located at United States, North America.
“Antiva is developing novel topical therapies to treat pre-cancerous lesions caused by HPV.”

Company website: http://www.antivabio.com